Japanese drugmaker Astellas Pharma says it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labor ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for ...

York-based biotech firm, the Aptamer Group, has reported “Revenue growth and significant commercial and technical progress” in its ...

In this roundtable discussion, an expert panel will discuss how the latest applications of aptamer technology are enabling innovation across the life sciences by replacing antibodies. Experts from the ...

Given the promising development and potential application of aptasensors, future research studies made will witness the great practicality of using aptamer-based biosensors within the field of food ...

Lastly, the identified aptamer sequences were also effective in recognition of fusion proteins, which greatly expands the scope of potential applications of such aptamers. This work suggested that the ...